Why this site.exists

Peptide therapy is a serious branch of human medicine. It also happens to be a branch that big pharmaceutical companies have very little incentive to develop, market, or stand behind. PEP/NEWS exists to fill the resulting information gap.

You don't need a tinfoil hat to notice that the medications being most aggressively advertised on television are the ones with twenty-line side-effect disclaimers. You also don't need one to notice that the kinds of therapies showing real promise for tissue repair, metabolic function, longevity, and inflammatory disease — peptides, in particular — are the ones you almost never hear about on the same channels.

That gap isn't a coincidence. It's a business model.

Peptides aren't easily patentable. So they aren't easily marketable. So they aren't easily profitable. So they aren't talked about.

What we mean.by "managed decline"

Managed decline is the term researchers use when they describe healthcare systems that are organized around treating chronic disease at scale, rather than reversing or preventing it. It's not malice. It's incentives. The companies that make the most money treating diabetes don't make less money if there are more diabetics — they make more.

Peptide therapies sit in an awkward place in that incentive structure. Many of them target the underlying mechanisms of disease and aging — mitochondrial function, autophagy, growth-factor signaling, gut barrier integrity, telomere maintenance. The research record is genuinely interesting. But because the molecules are small, naturally occurring, and difficult to lock down with intellectual property, the standard pharmaceutical development pipeline doesn't reach for them. The result is a body of evidence that lives in academic journals, foreign clinics, and underground forums — but rarely in your doctor's office or your prescription drug ad.

Most of what we cover on PEP/NEWS came from research groups working without big pharma money. A meaningful share of it came from labs in countries where the regulatory frame for peptides is more permissive than ours. Some of it is preliminary. Almost none of it has been packaged for the average consumer. We try to translate it without dumbing it down.

What we are.What we aren't

What we cover.How we cover it

Every day around UTC noon, an automated pipeline pulls fresh content from a wide list of peptide-research RSS feeds (peer-reviewed journals, biotech industry wires, longevity research outlets) and a curated list of YouTube channels of physicians and researchers who treat peptide therapy seriously. A real LLM reads the lot and picks the day's brief — one hero story, several featured pieces (some video, some article), and a short list of additional headlines worth knowing.

When peptide names appear in our briefs, we link out to the original sources. Where it makes sense, we also discreetly cross-link to where research-grade material can be sourced; that's how we keep the lights on. The editorial decisions are independent of those links.

Why now.Why this

Because you'll never get the right answer if you only listen to people whose paychecks depend on the wrong question. Because the people most actively researching peptide therapy are publishing in places most people don't read. Because the difference between living a full life and a managed one often comes down to information access. And because someone needs to do the curation that the algorithms refuse to.

We're a small operation. The site will grow as the audience does. If you found something useful here, that's the only metric that matters.

Tip line: tips@pep.news